JAK2 Human TK Kinase Enzymatic Radiometric LeadHunter Assay [10 μM ATP] - TW
OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
Janus kinase 2 (JAK2) is a nonreceptor tyrosine kinase belonging to the Janus family. It is activated by a variety of cytokine and growth factor receptors, resulting in signaling cascades that facilitate the activation of various downstream target genes. JAK2 mediates gene transcription through its well-characterized downstream signaling molecules, the signal transducers and activators of transcription proteins (STAT).
Family:
Kinase
Sub Family:
TK
Class:
Protein Tyrosine
Protein Name:
JAK2
Uniprot Number:
O60674
Protein Aliases:
JAK-2
Gene Name:
JAK2
Gene ID:
3717
Gene Aliases:
JTK10
Accession Number:
NM_001322195
Organism:
Human
Construct Details:
Fragment (809-1132), Recombinant
Assay Information
Assay Type:
Biochemical
Assay Sub Type:
Enzymatic
Functional Mode:
Antagonist
Detection Method:
Radiometry
Measured Response:
Scintillation
Testing Information
Procedure Summary:
Human recombinant protein kinase JAK2 expressed in insect cells is used. Test compound and/or vehicle is preincubated with 1.5 µg/ml enzyme‡ for 15 minutes at 37°C in modified HEPES buffer pH 7.4. The reaction is initiated by addition of 0.2 mg/ml poly(Glu:Tyr), 10 µM ATP containing 0.25 µCi [γ32P]ATP for 30 minutes and terminated by further addition of 3% H3PO4. An aliquot is counted to determine the radioactivity of [32P]Poly(Glu:Tyr). Compounds are screened at 10 µM.
Substrate:
200 µg/ml Poly(Glu:Tyr)
ATP Concentration:
10 uM
Incubation:
30 min at 37°C
Control Inhibitor:
Staurosporine
Criteria For Significance:
≥ 50% of max stimulation or inhibition
Test Concentration / Dose:
Suggested concentration for initial testing is 10 uM
Test Sample Requirements:
Minimum for 1) Screen: 25 μl of 10 mM stock -OR- 1 mg (pre-weighed). 2) Dose Response: 60 μl of 10 mM stock -OR- 1 mg (pre-weighed).
Minimum Order Quantity:
10
Turnaround Time
Standard:
15 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology
Adverse / Beneficial Action:
Inhibition of JAK2 may impair erythropoietin (EPO)-induced erythropoeiesis and protection from bain damage following hypoxia. Inhibition may also adversely effect diabetes.
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei
RELATED SOLUTIONS
JAK3 Human TK Kinase Enzymatic Radiometric LeadHunter Assay [10 μM ATP] - TW
Item: 174080
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
